Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report.

BRAF inhibitors cryopreservation male fertility metastatic melanoma sperm DNA

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 02 08 2019
accepted: 11 02 2020
entrez: 27 3 2020
pubmed: 27 3 2020
medline: 27 3 2020
Statut: epublish

Résumé

Melanoma is a frequent neoplasm in young adult males in reproductive age, 10% of them degenerating into regional and/or distant metastases (MM). The use of BRAF inhibitors (BRAFi) vemurafenib and dabrafenib is effective in MM patients harboring

Identifiants

pubmed: 32211316
doi: 10.3389/fonc.2020.00232
pmc: PMC7066495
doi:

Types de publication

Case Reports

Langues

eng

Pagination

232

Informations de copyright

Copyright © 2020 Ghezzi, Garolla, Magagna, Šabovich, Berretta, Foresta and De Toni.

Références

N Engl J Med. 2010 Aug 26;363(9):809-19
pubmed: 20818844
Oncotarget. 2017 Dec 7;9(3):3060-3068
pubmed: 29423028
J Endocrinol Invest. 2013 Jun;36(6):379-84
pubmed: 23047203
J Clin Pharmacol. 2014 Jun;54(6):696-706
pubmed: 24408395
Cancer Cell. 2004 Oct;6(4):313-9
pubmed: 15488754
Asian J Androl. 2015 Mar-Apr;17(2):236-8
pubmed: 25248651
Neoplasma. 2009;56(6):473-9
pubmed: 19728753
Nature. 2010 Sep 30;467(7315):596-9
pubmed: 20823850
J Clin Oncol. 2005 Sep 20;23(27):6771-90
pubmed: 16170185
J Dtsch Dermatol Ges. 2015 Apr;13(4):277-89; quiz 290
pubmed: 25819232
ESMO Open. 2019 May 23;4(3):e000491
pubmed: 31231568
Lancet. 2014 Oct 4;384(9950):1302-10
pubmed: 25283571
Lancet. 2010 Oct 16;376(9749):1301
pubmed: 20951890
Front Pharmacol. 2016 May 13;7:122
pubmed: 27242529
Cancer. 2012 Aug 15;118(16):4014-23
pubmed: 22180178
Andrology. 2017 Jul;5(4):711-717
pubmed: 28544654
Clin Cancer Res. 2017 Sep 15;23(18):5339-5348
pubmed: 28611198
Clin Cancer Res. 2014 Sep 1;20(17):4449-58
pubmed: 24958809
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Am J Mens Health. 2018 May;12(3):628-633
pubmed: 27489147
Nat Rev Clin Oncol. 2010 Aug;7(8):466-75
pubmed: 20498666
Int J Androl. 2011 Dec;34(6 Pt 2):e511-7
pubmed: 21790654
N Engl J Med. 2005 Nov 17;353(20):2135-47
pubmed: 16291983
N Engl J Med. 2009 Feb 26;360(9):902-11
pubmed: 19246362
J Am Acad Dermatol. 2016 Sep;75(3):528-534
pubmed: 27543212
Acta Oncol. 2018 Aug;57(8):1131-1133
pubmed: 29526130
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
Reprod Fertil Dev. 1995;7(4):799-809
pubmed: 8711214
Reprod Biomed Online. 2015 Jul;31(1):100-7
pubmed: 25985994
Andrology. 2017 Sep;5(5):898-904
pubmed: 28591464
Endocr Dev. 2009;15:101-134
pubmed: 19293606
Fed Regist. 2014 Dec 4;79(233):72063-103
pubmed: 25509060

Auteurs

Marco Ghezzi (M)

Department of Clinical and Experimental Oncology, IOV-IRCCS, Padua, Italy.
Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padua, Padua, Italy.

Andrea Garolla (A)

Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padua, Padua, Italy.

Sabina Magagna (S)

Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padua, Padua, Italy.

Iva Šabovich (I)

Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padua, Padua, Italy.

Massimiliano Berretta (M)

Department of Medical Oncology, National Cancer Institute, IRCCS Aviano, Aviano, Italy.

Carlo Foresta (C)

Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padua, Padua, Italy.

Luca De Toni (L)

Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padua, Padua, Italy.

Classifications MeSH